The short answer: can you afford it?
The affordability test for buying a pharmacy has three components: whether your deposit (from savings, equity, or other sources) covers the lender's required stake; whether the loan repayments fit within projected income; and whether post-tax cash from the pharmacy's projected profit covers annual debt service and leaves a drawings buffer. All three must pass. Failing one means the purchase is unaffordable at the proposed price, regardless of how attractive the opportunity looks on the surface. The pharmacy purchase affordability calculator walks through each component in turn as a scenario estimate.
This post explains each component at method level, without invented lender rates or deposit percentages (those are lender-specific and change frequently). The goal is to show you how the arithmetic works so you can sense-check a deal before committing to professional fees and legal costs.
The three inputs: deposit, loan, and post-tax cash cover from projected profit
Every pharmacy affordability assessment starts with the same three numbers. The interplay between them is what first-time buyers most often underestimate.
The deposit
The deposit is the portion of the purchase price you fund without borrowing. Lenders set their own deposit requirements based on the deal, the quality of the accounts, the pharmacy's income mix, and their own appetite at the time. No universal percentage applies, and any figure you see quoted online is a broker's illustrative example, not a guarantee.
What matters for your planning is the source of the deposit: personal savings, equity release from another property, or a combination. Each source has different tax and cash-flow implications that a pre-purchase review should map out before you approach a lender.
The loan
The loan covers the gap between the purchase price and the deposit. Pharmacy loans are typically commercial loans rather than residential mortgages, structured around the business's ability to service the debt from income. The loan term, interest rate, and repayment structure are agreed with the lender and directly determine the annual debt-service figure the pharmacy's post-tax profit must exceed.
Post-tax cash cover from projected profit
This is the test most first-time buyers get wrong. The figure that matters is not the pharmacy's headline profit or adjusted EBITDA. It is the cash left after tax.
- If you are buying through a company, corporation tax applies first. The main rate is 25% on profits above £250,000 and 19% on profits up to £50,000, with marginal relief between the two thresholds (limits divided by the number of associated companies). See HMRC corporation tax rates. Most single-store pharmacy buyers sit in the marginal band.
- If you are buying as a sole trader or partnership, income tax and Class 4 NIC apply instead, at the relevant bands for your total income.
- Dividend extraction from a company adds a second layer: dividends are paid from post-corporation-tax profit and then taxed at 10.75%, 35.75%, or 39.35% (FA 2026 rates for 2026/27) with a £500 dividend allowance. Salary/dividend mix planning is part of the true cost of ownership.
Once you know the post-tax cash figure, the affordability test is:
Post-tax cash minus annual debt service (capital plus interest) minus a drawings buffer = headroom.
Positive headroom means the purchase is cash-flow affordable at the projected profit level. Thin or negative headroom means the price, the loan structure, or the projected income need to change.
Illustrative affordability worksheet (example figures only)
The table below shows the structure of the calculation, not a real-world outcome. The figures are illustrative and internally consistent. They are not a lender's offer and not a guarantee of any particular result.
| Line | Illustrative amount | Note |
|---|---|---|
| Purchase price | £500,000 | Example only |
| Deposit | (£100,000) | Buyer's own funds |
| Loan required | £400,000 | To be agreed with lender |
| Projected adjusted profit | £80,000 | From vendor's accounts, adjusted |
| Corporation tax (marginal, illustrative) | (£20,000) | Actual rate depends on associated companies and profit level |
| Post-tax profit available | £60,000 | |
| Annual debt service (illustrative) | (£40,000) | Lender-specific; not a quoted rate |
| Drawings buffer required | (£30,000) | Living costs, owner-specific |
| Headroom | (£10,000) | Negative: purchase is unaffordable at these figures |
In this example, the projected profit does not cover both debt service and drawings at the proposed price. The buyer would need to renegotiate the price, increase the deposit, or identify a higher-profit pharmacy. The purchase affordability calculator lets you adjust each variable to find where headroom turns positive. It is a scenario tool, states its simplifications, and ends at "your situation warrants a specialist review", not at a specific lender offer.
Why the NHSBSA payment lag matters to affordability
Pharmacy income is contract-driven, not till-driven. The primary income source is NHS reimbursement under the Community Pharmacy Contractual Framework, not shop takings. As a result, the cash-flow pattern is unlike most retail businesses.
FP34 prescriptions are submitted monthly to the NHSBSA and payment arrives roughly two months later, with an advance on account. That two-month lag means that in the first weeks of ownership you are dispensing and staffing without receiving the full income from those prescriptions yet. The advance smooths some of this, but a working-capital buffer is still needed on day one, in addition to the deposit and legal costs of the purchase.
First-time buyers who model affordability on the pharmacy's annual profit figure without accounting for this timing gap can find themselves cash-constrained immediately after completion, even if the underlying business is profitable. Finance-ready accounts and a cash-flow projection that shows the NHSBSA payment cycle are part of what a specialist buyer review covers. For more on FP34 mechanics, see our NHS payment reconciliation service.
What "finance-ready accounts" means
Lenders and professional advisers assessing a pharmacy purchase need accounts that go beyond what a standard bookkeeper produces. Finance-ready accounts for a pharmacy have four characteristics.
Clean and reconciled
NHS income is reconciled back to NHSBSA schedules, not just recognised as a bank receipt. VAT is correctly split between zero-rated prescription dispensing and standard-rated OTC retail, as set out in HMRC Notice 701/57. A pharmacy is a VAT-mixed business and the split matters because it affects both the true revenue figure and the VAT reclaim position. Unreconciled accounts mask the real margin and raise questions a buyer's adviser will need to resolve before recommending proceeding.
Margin story evidenced
Drug Tariff and Category M reimbursement prices are set centrally and adjusted retrospectively by the NHSBSA. That means gross margin is not fixed; it varies with Drug Tariff revisions and can be affected by clawback. Finance-ready accounts show the margin trend over at least two full years, explain any significant variations, and present an adjusted EBITDA that removes one-off items so the ongoing earning capacity is visible.
Service income separately tracked
Pharmacy First and similar service payments are a separately accounted income line with their own fee structure. Accounts that lump service income into general turnover make it harder to assess how dependent the business is on dispensing volume versus growing service revenue.
Owner-related costs adjusted
Where the vendor has run personal costs through the business, or where the owner-pharmacist's salary is above or below a market locum rate, adjusted EBITDA must be restated to reflect the true cost of operating under new ownership. Lenders and advisers will do this adjustment themselves if the accounts do not; the cleaner the starting point, the less uncertainty there is about the adjustment.
Finance-ready accounts checklist
| Item | Why a lender or adviser needs it |
|---|---|
| 2 to 3 years of filed statutory accounts | Trend visibility; consistency check against management accounts |
| NHSBSA payment schedules reconciled to P&L | Confirms revenue is real and correctly timed |
| VAT returns showing zero-rated / standard-rated split | Verifies the VAT-mixed position and reclaim accuracy |
| Drug Tariff adjustment history (at least 12 months) | Shows margin stability and clawback exposure |
| Adjusted EBITDA schedule (one-offs removed, owner costs normalised) | Establishes the true ongoing earning capacity |
| Dispensing volume history (items per month) | Cross-checks revenue and shows trajectory |
| Service income breakdown (Pharmacy First, other) | Separates growing service revenue from core dispensing income |
| Cash-flow forecast showing NHSBSA payment lag | Models working-capital requirement in first months of ownership |
How the numbers actually stack: a method-level walk-through
A pharmacy purchase price is typically derived from a multiple of adjusted EBITDA and cross-checked against a pence-per-item benchmark on dispensing volume. Neither method produces a single correct answer, and the multiple and benchmark vary with the pharmacy, the contract terms, the location, and current market conditions. We do not publish a specific multiple because no single figure holds across deals.
What the method tells you is this: the higher the price relative to adjusted EBITDA, the more years of post-tax profit are needed to service the acquisition debt. A purchase at a high multiple with thin margins produces a tight debt-service cover ratio. A purchase at a lower multiple with a growing Pharmacy First income line and stable dispensing volume may be strongly affordable at the same absolute price. The arithmetic, not the headline multiple, is the test.
Running the affordability worksheet for yourself, with the actual accounts and a realistic loan structure, is the only way to know whether a specific pharmacy is affordable for your specific financial position. The purchase affordability calculator is built to do this work without requiring a spreadsheet, but it is a scenario tool and does not produce a lender offer or a tax return figure.
Structure affects affordability: share purchase versus asset purchase
The legal structure of the deal changes what you are financing and what the tax costs of entry are, both of which affect affordability.
In a share purchase, you buy the company that holds the NHS contract and the pharmacy business. Stamp duty of 0.5% on the share consideration applies. You also inherit the company's history, including any historic tax liabilities, so pre-purchase due diligence is more extensive. The NHS contract stays in the company, avoiding a separate NHS contract transfer process.
In an asset purchase, you buy the individual assets (goodwill, stock, fixtures) rather than the company. If property is included, SDLT at non-residential rates up to 5% applies. Goodwill dominates pharmacy pricing (driven by the NHS contract and dispensing volume), and corporation tax relief on goodwill acquired by a company is restricted in most cases, reducing the after-tax cost efficiency of the deal for a company buyer.
The structure decision also affects how the NHS contract is transferred and the GPhC registration steps, as set out in the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. The deep-dive on share versus asset is in our share versus asset purchase guide. For affordability purposes, note that the entry tax costs (stamp duty, SDLT) are part of the total cash needed on day one, not just the purchase price.
What a specialist checks before you commit
A pre-purchase accounting review does several things a lender or solicitor will not do for you.
- It reconstructs adjusted EBITDA from the vendor's accounts, removing one-offs and normalising owner costs, to give a defensible post-tax cash figure before you negotiate the price.
- It maps the NHSBSA payment lag against your available working capital to confirm you will not run short in the first quarter.
- It reviews the VAT-mixed position and flags any historic errors that become your liability in a share purchase.
- It models the post-tax cash cover under your planned ownership structure (company or sole trader, salary and dividend mix) so the headroom figure is your actual headroom, not a vendor's illustration.
- It identifies whether the goodwill and fit-out assets are properly classified for capital allowances purposes, which affects year-one and year-two tax.
If you are at an early stage and want to run the numbers before instructing specialists, start with the pharmacy purchase affordability calculator. If you are closer to a deal and need a detailed pre-purchase review, our pharmacy purchase accounting service covers the full scope above. For a broader overview of the process from search to completion, the buying a pharmacy checklist sets out each stage. For the audience hub with links to all buying-related resources, see buying a pharmacy.
This post gives general accounting and tax information about pharmacy purchase affordability. It is not financial promotion, lending advice, or a personal recommendation. Figures described as illustrative are examples only and do not represent any lender's criteria or a guaranteed outcome. Speak to a qualified specialist before making any purchase decision.